Patents by Inventor Jason P. Hodde
Jason P. Hodde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200188559Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: February 26, 2020Publication date: June 18, 2020Applicant: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Patent number: 10471182Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: GrantFiled: October 25, 2016Date of Patent: November 12, 2019Assignee: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Publication number: 20190336650Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: June 26, 2019Publication date: November 7, 2019Applicant: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Publication number: 20180228939Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: December 15, 2017Publication date: August 16, 2018Applicant: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Publication number: 20170128628Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: October 25, 2016Publication date: May 11, 2017Inventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Patent number: 9504769Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: GrantFiled: September 6, 2011Date of Patent: November 29, 2016Assignee: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M. J. Ernst, Lal Ninan
-
Patent number: 9138445Abstract: Described are medical grafting materials that include a base substrate material and an adherent fibrous mass of extracellular matrix components received upon the substrate material. Also described are methods of preparing and using such materials.Type: GrantFiled: March 9, 2006Date of Patent: September 22, 2015Assignee: Cook Biotech IncorporatedInventor: Jason P. Hodde
-
Patent number: 8784889Abstract: Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures of two or more such acids.Type: GrantFiled: January 30, 2007Date of Patent: July 22, 2014Assignee: Cook Biotech IncorporatedInventors: Jason P. Hodde, David M. J. Ernst
-
Patent number: 8741352Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: GrantFiled: September 7, 2007Date of Patent: June 3, 2014Assignee: Cook Biotech IncorporatedInventors: Jason P. Hodde, David M. J. Ernst, Lal Ninan, Sherry Voytik-Harbin, Nathan Hammond
-
Publication number: 20110318419Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Inventors: Michael C. Hiles, Jason P. Hodde, David M.J. Ernst, Lal Ninan
-
Patent number: 8021692Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibrob-last Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: GrantFiled: August 25, 2004Date of Patent: September 20, 2011Assignee: Cook Biotech IncorporatedInventors: Michael C. Hiles, Jason P. Hodde, David M. J. Ernst, Lal Ninan
-
Patent number: 7959554Abstract: Described are methods and systems for drying remodelable materials, such that selective regions of the remodelable materials have differing properties. Also described are medical graft products having selective regions of differing material properties. Advantageous remodelable materials include collagenous extracellular matrix material, such as small intestine submucosa.Type: GrantFiled: September 19, 2006Date of Patent: June 14, 2011Assignee: Cook Biotech IncorporatedInventors: Chad S. McAlexander, Clay Fette, Jason P. Hodde, Matthew R. Graham
-
Publication number: 20100266654Abstract: Described are medical compositions including a collagenous ECM particulate dispersed in a carrier. Such medical compositions can be applied to at least a portion of a surface of a sheet of collagenous ECM material to form a medical product. Medical compositions and products as described herein find particular use in wound repair. Related methods of manufacture and use are also described.Type: ApplicationFiled: June 28, 2010Publication date: October 21, 2010Inventors: Jason P. Hodde, Umesh H. Patel
-
Publication number: 20100196480Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: April 16, 2010Publication date: August 5, 2010Inventors: Michael C. Hiles, Jason P. Hodde, David M. J. Ernst, Lal Ninan
-
Patent number: 7745217Abstract: The invention provides tissue graft compositions comprising collagen-based extracellular matrices derived from renal capsules of warm-blooded vertebrates. The invention further provides a process of harvesting and purifying a renal capsule to provide an extracellular matrix material having beneficial use as a tissue graft and/or cell growth material.Type: GrantFiled: July 11, 2006Date of Patent: June 29, 2010Assignee: Cook Biotech IncorporatedInventors: Umesh H. Patel, Michael C. Hiles, Jason P. Hodde
-
Patent number: 7087089Abstract: The invention provides tissue graft compositions comprising collagen-based extracellular matrices derived from renal capsules of warm-blooded vertebrates. The invention further provides a process of harvesting and purifying a renal capsule to provide an extracellular matrix material having beneficial use as a tissue graft and/or cell growth material.Type: GrantFiled: June 28, 2002Date of Patent: August 8, 2006Assignee: Cook Biotech IncorporatedInventors: Umesh H. Patel, Michael C. Hiles, Jason P. Hodde
-
Publication number: 20030014126Abstract: The invention provides tissue graft compositions comprising collagen-based extracellular matrices derived from renal capsules of warm-blooded vertebrates. The invention further provides a process of harvesting and purifying a renal capsule to provide an extracellular matrix material having beneficial use as a tissue graft and/or cell growth material.Type: ApplicationFiled: June 28, 2002Publication date: January 16, 2003Inventors: Umesh H. Patel, Michael C. Hiles, Jason P. Hodde
-
Patent number: 6375989Abstract: A method for preparing a bioactive extract from warm-blooded vertebrate submucosal tissue is described. The submucosal tissue is extracted using an aqueous solution of extraction excipients, and the extracted bioactive components are then separated from the extraction excipients to provide an isolated extract enriched in bioactive components. The isolated extract is useful, inter alia, as additive for cell growth media to promote cell growth and proliferation in vitro.Type: GrantFiled: June 10, 1999Date of Patent: April 23, 2002Assignee: Purdue Research FoundationInventors: Stephen F. Badylak, Andrew O. Brightman, Jason P. Hodde, Timothy B. McPherson, Sherry L. Voytik-Harbin